Schizophrenia is a complex and chronic brain disorder that affects a person’s ability to think, feel, and behave clearly. Understanding the causes of schizophrenia is crucial for effective diagnosis and management. While the exact causes remain unknown, research indicates a combination of genetic predisposition, perinatal factors, and possibly socioenvironmental influences contribute to the development of this condition. This article delves into these key risk factors, providing an overview that is essential for grasping the complexities of schizophrenia and its diagnosis, particularly within the framework of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition).
Genetic Predisposition to Schizophrenia
Genetics plays a significant role in schizophrenia. The risk is substantially higher in individuals with biological relatives who have the disorder. Studies consistently show that the risk escalates with the closeness of the genetic relationship. For instance, a first-degree relative of a person with schizophrenia has a 10% chance of developing the condition. This risk jumps dramatically to 40% if both parents are affected. Twin studies further illustrate the strong genetic component, with monozygotic (identical) twins showing a concordance rate of 40-50%, compared to approximately 10% for dizygotic (fraternal) twins. This highlights that while genetics is not the sole determinant, it establishes a significant vulnerability.
Alt text: Depiction of a DNA double helix, symbolizing the complex genetic factors involved in schizophrenia.
Genome-wide association studies (GWAS) have been instrumental in identifying numerous candidate genes associated with schizophrenia. These studies analyze the genomes of large groups of people to find genetic variations linked to the disease. While many genes have been implicated, each individual gene variant identified so far accounts for only a small fraction of cases, and findings often require replication across different studies to be confirmed. These genes primarily influence gene expression or protein function in subtle ways, suggesting a polygenic nature to schizophrenia, where multiple genes contribute to the overall risk.
Recent research continues to uncover the intricate genetic architecture of schizophrenia. A 2021 study by Cheng et al. explored the genetic overlap between schizophrenia and brain cortical surface area (SA) and thickness (TH). Utilizing GWAS data from over 139,000 participants, they discovered that a significant portion of genetic variants associated with cortical SA and TH are also linked to schizophrenia risk. This study, employing a statistical tool called MiXeR, indicated that schizophrenia is more polygenic than total SA and average TH. Notably, the study estimated that a vast majority (93.6%) of single-nucleotide variants (SNVs) associated with total SA might also be connected to the development of schizophrenia. This suggests that genes influencing brain structure also play a crucial role in schizophrenia susceptibility.
A landmark 2014 study further expanded our understanding by identifying 108 genetic loci associated with schizophrenia, with 83 of these being newly discovered. This research not only reinforced the involvement of brain-expressed genes but also highlighted enriched associations among genes expressed in immune-related tissues. This finding lends support to the emerging theory linking the immune system to the pathophysiology of schizophrenia, indicating a broader systemic involvement beyond just the brain.
Certain genes have garnered particular attention in schizophrenia research due to their specific functions and consistent associations. These include:
-
Catechol-O-methyltransferase (COMT) gene: This gene encodes for the COMT enzyme, which is vital for degrading neurotransmitters like dopamine, epinephrine, and norepinephrine. Variations in the COMT gene affect its enzyme activity. For example, the valine-valine variant degrades dopamine more rapidly than the valine-methionine variant. Interestingly, individuals with two copies of the methionine allele showed a reduced likelihood of developing psychotic symptoms from cannabis use compared to those without this variant, suggesting a gene-environment interaction.
-
RELN gene: The RELN gene provides instructions for making reelin, a protein crucial for brain development and GABAergic neurotransmission. An international study identified a common variant in RELN that increases schizophrenia risk, specifically in women, highlighting potential sex-specific genetic vulnerabilities.
-
Nitric oxide synthase 1 adaptor protein (NOS1AP) gene: This gene codes for nitric oxide synthase, an enzyme abundant in inhibitory neurons and involved in intracellular signaling. Researchers, using advanced statistical methods, have linked a specific single-nucleotide polymorphism in NOS1AP to higher gene expression levels in postmortem brain samples from individuals with schizophrenia, suggesting a role in the disorder’s neurobiology.
-
Metabotropic glutamate receptor 3 (GRM3) gene: GRM3 is associated with bipolar disorder and schizophrenia. A 2014 study revealed a variant in GRM3 that increases the risk of schizophrenia, alcohol dependence, and bipolar disorder. This variant, found in approximately 1 in 200 people, might represent a non-specific risk factor for various mental disorders, making it a potential target for broader psychiatric treatments.
Beyond specific gene variants, structural changes in genes, known as copy number variants (CNVs), also contribute to schizophrenia risk. CNVs are deletions or duplications of DNA segments that can affect genes or regulatory regions. While often inherited, they can also arise spontaneously. CNVs at loci such as 1q21.1, 15q13.3, and 22q11.2 are associated with increased schizophrenia risk. However, it’s important to note that these genetic findings, including CNVs, likely explain only a portion of the heritability of schizophrenia, indicating the involvement of other genetic and environmental factors.
Furthermore, the impact of CNVs is not exclusive to schizophrenia. These genetic variations are also implicated in other neurodevelopmental conditions like autism, intellectual disability, ADHD, and epilepsy, suggesting shared genetic vulnerabilities across these disorders. A study examining 39,000 individuals referred for genetic testing found that about 1000 carried a CNV at specific loci (1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p13.11, and 22q11.2). Clinically, these individuals presented with a range of neurological and psychiatric disorders, including developmental delay, intellectual disability, autism spectrum disorder, and congenital anomalies.
Research has also focused on neurodevelopmental genes, with disruptions in genes like DISC1, NRG1, DTNBP1, KCNH2, AKT1, and RGS4 being linked to schizophrenia, although with variability across studies. These findings support the hypothesis that schizophrenia can be a result of multiple rare genetic variants converging towards a common clinical outcome.
Interestingly, some individuals with schizophrenia have no family history of the disorder. These cases may arise from de novo mutations, new genetic changes not inherited from parents. Exome sequencing studies have shown that de novo mutations in the exome (the protein-coding part of the genome) are more frequent in schizophrenia patients than expected. These mutations often cluster in proteins involved in brain function and overlap with mutations seen in autism and intellectual disability, further highlighting shared genetic pathways across neurodevelopmental disorders.
A large genome-wide association study involving Swedish samples and replication cohorts found clustering at 22 loci, 14 of which were novel. Most of the identified single-nucleotide polymorphisms (SNPs) were common, and collectively, they could account for a significant portion of the variance in schizophrenia liability. This suggests that common genetic variation also plays a crucial role in schizophrenia, similar to other complex diseases like coronary artery disease.
Schizophrenia and bipolar disorder are believed to share substantial genetic risk factors, although only a fraction of this shared genetic risk has been identified to date. Unraveling the complexities of these genetic factors is an ongoing challenge. Interactions within the genome and with environmental factors are undoubtedly critical. However, a meta-analysis of twin studies estimates that genetic factors account for approximately four-fifths of the susceptibility to schizophrenia, underscoring the strong heritability of the disorder.
Perinatal Complications and Schizophrenia Risk
Perinatal factors, encompassing events around the time of birth, are increasingly recognized as significant contributors to schizophrenia risk. Maternal malnutrition and certain viral infections during pregnancy have been associated with a higher likelihood of offspring developing schizophrenia later in life. For example, children born to Dutch mothers who experienced malnutrition during World War II showed an elevated rate of schizophrenia.
Alt text: A pregnant woman gently holding her stomach, representing the importance of maternal health during pregnancy in relation to fetal development and potential schizophrenia risk.
The influenza A2 epidemics of 1957 in Japan, England, and Scandinavia were followed by increased schizophrenia rates in offspring of women who contracted influenza during their second trimester. Similarly, a study in California between 1959 and 1966 found that mothers who had influenza during the first trimester were more likely to have children who later developed schizophrenia.
Obstetric complications are also linked to a higher incidence of schizophrenia. Furthermore, children born during winter months may have a slightly increased risk of developing schizophrenia, although the reasons for this are not fully understood and may relate to seasonal variations in infections or other environmental factors.
A Finnish study investigating women with upper urinary tract infections during pregnancy provides further insight into the interplay between genetic and environmental influences in schizophrenia. This study reviewed data from nearly 10,000 women in Helsinki hospitalized for upper urinary tract infections during pregnancy between 1947 and 1990. While no overall significant increase in schizophrenia risk was found in their offspring, a striking 5-fold higher risk emerged among offspring of women who also had a family history of psychosis. The researchers estimated that in offspring with both prenatal pyelonephritis and a family history of psychotic disorders, 38-46% of schizophrenia cases could be attributed to the synergistic effect of these two risk factors. This study powerfully illustrates how genetic vulnerability can interact with environmental insults during prenatal development to elevate schizophrenia risk.
Drug Use and Early Psychosis Onset
Substance use, particularly cannabis, has been investigated in relation to schizophrenia, especially concerning the age of onset of psychosis. A recent study suggests that heavy marijuana use in teenagers aged 15–17 years may accelerate the onset of psychosis in individuals already at high risk for developing a psychotic disorder.
The Allied Cohort on the Early course of Schizophrenia (ACES) II project analyzed 247 hospitalized patients experiencing first-episode psychosis. The study found that in patients who used cannabis heavily from ages 15 to 17, the onset of psychosis occurred at a mean age of 21.07 years, significantly earlier than the mean age of 23.86 years in patients who did not use cannabis during those teenage years. However, it’s crucial to note that this study, like others in this area, cannot definitively establish a causal relationship. It remains unclear whether marijuana use directly causes an earlier onset of psychosis, or whether individuals predisposed to earlier psychosis are also more likely to use marijuana due to various underlying factors. Regardless, this association highlights the importance of considering substance use history, particularly in adolescence, when assessing individuals at risk for or experiencing early signs of psychosis.
DSM-5 Diagnostic Criteria and the Role of Etiological Understanding
While the DSM-5 focuses on symptom-based criteria for diagnosing schizophrenia, understanding the etiological factors, such as genetic and perinatal risks, provides crucial context for diagnosis and comprehensive patient care. The DSM-5 outlines specific criteria for schizophrenia diagnosis, including characteristic symptoms (delusions, hallucinations, disorganized thinking, negative symptoms), social or occupational dysfunction, duration of at least six months, and exclusion of other conditions like schizoaffective disorder and mood disorders with psychotic features, and ruling out substance use or general medical conditions as direct causes.
While genetic and perinatal factors are not direct diagnostic criteria in DSM-5, knowledge of these risk factors can inform clinical assessment and risk stratification. For instance, individuals with a strong family history of schizophrenia presenting with early, subtle symptoms might warrant closer monitoring and earlier intervention. Similarly, a history of perinatal complications in conjunction with emerging psychotic symptoms could increase clinical suspicion for schizophrenia.
In conclusion, schizophrenia is a multifaceted disorder with a complex interplay of genetic, perinatal, and potentially environmental risk factors. While genetic vulnerability constitutes a substantial component of risk, perinatal events and possibly substance use, particularly during critical developmental periods, can further modulate this risk and influence the trajectory of the illness. Understanding these etiological factors, alongside the DSM-5 diagnostic framework, is essential for a comprehensive approach to diagnosing, treating, and ultimately preventing schizophrenia and related psychotic disorders. Further research is needed to fully elucidate the intricate interactions between genes, environment, and individual vulnerabilities in the development of schizophrenia, paving the way for more targeted and effective interventions.
